Novantrone
(mitoxantrone hydrochloride)ApprovedSmall molecule
PfizerMitoxantrone is used to treat certain types of cancer, including leukemia and lymphoma, and is also used to reduce symptoms in patients with multiple sclerosis. It works by damaging cancer cell DNA to stop them from growing and dividing.[2] Novantrone is currently approved and in use across 36 indications[4].[1]
Novantrone is one of 767 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Approved.
36
Indications
121
Total Trials
7
Active Trials
766
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 36 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Novantrone
PfizerApproved
Halaven
EisaiPreclinical
Tecentriq
RochePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Avastin
RochePreclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia32 trials
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Completed·—·Phase 1·NCT02070458·30 enrolled
Show 29 more trials
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00006122·106 enrolled
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002719·500 enrolled
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Completed·—·Phase 1·NCT01127009·3 enrolled
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00052299·472 enrolled
Lymphoma15 trials
Show 12 more trials
Metastatic Prostate Cancer9 trials
Show 6 more trials
Leukemia8 trials
Show 5 more trials
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
Completed·—·Phase 1·NCT00003003·29 enrolled
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
Completed·—·Phase 2·NCT00047021·3 enrolled
Breast Cancer7 trials
21 more indications
Acute Lymphoblastic Leukemia7 trials
Prostate Cancer5 trials
Chronic Lymphocytic Leukemia4 trials
Acute Leukemia4 trials
Myelodysplastic Syndrome4 trials
Acute Promyelocytic Leukemia3 trials
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled
Ovarian Cancer3 trials
Myelodysplastic Syndromes3 trials
Myeloid Neoplasm2 trials
Bone Marrow Transplantation2 trials
Newly Diagnosed2 trials
Chronic Myelogenous Leukemia2 trials
Ovarian Epithelial Cancer1 trial
Kaposi's sarcoma1 trial
Chemotherapy1 trial
Hematologic Cancer1 trial
Multiple Myeloma1 trial
B-cell acute lymphoblastic leukemia1 trial
Juvenile Myelomonocytic Leukemia1 trial
Thyroid Cancer1 trial
Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery
Not yet recruiting·—·Phase 4·NCT07354698·114 enrolled
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Novantrone drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for mitoxantrone hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [5]